Divi’s Laboratories Ltd is a Hyderabad-based pharmaceutical company. It is a leading manufacturer of active pharmaceutical ingredients (APIs) and supplies its products to more than 100 countries. The company which is counted among the top API manufacturers in the world has been operating for the last 30 years.
Divi’s started as Divi’s Research Centre (DRC) in 1990. It set up its first manufacturing unit in Hyderabad in 1995 and received the USFDA inspection for the first time in 2000. The company set up its second manufacturing unit near Vishakhapatnam in 2002 and a year later was listed on BSE and NSE.
The company entered into the nutraceuticals segment in 2007. It also set up a new research unit in Hyderabad in 2010.
At present, Divi’s Laboratories has 16,500 trained professionals across departments and around 400 scientists working at its three research centres. It has two manufacturing facilities at Vizag and Hyderabad.
Business highlights
Divi’s Lab has a market valuation of Rs 98,600 crore as of December 19, 2023. Divi’s Lab shares price has dropped nearly 3% in three years.
The company’s business operations span across research and development activities and manufacturing operations. Its two main manufacturing facilities in Vizag and Hyderabad produce thousands of tonnes of APIs that are exported to around 100 countries.
Divi’s Laboratories have three main business segments:
Generic APIs
Divi’s Laboratories offers 30 generic active pharmaceutical ingredients to customers across the world. Its operations are bolstered by backward integration to basic starting materials, devoted production blocks with large batch sizes and significant capacity creation.
The company is a global leader in large-volume generic APIs. It looks to achieve global leadership in molecules and around 10 APIs are in the research and development stage. Its manufacturing plants have been audited by various regulatory authorities, as well as global environmental, health and safety teams.
Customs Synthesis
Divi’s Laboratories is involved in contract manufacturing services (custom synthesis) of APIs and intermediates for global companies. It has a portfolio of products across diverse therapeutic areas. The company has 12 out of the top 20 big pharma companies across US, Europe and Japan as its customers for more than 10 years.
Divi’s being a core generic API manufacturer has a research and development (R&D) team of more than 400 scientists.
Nutraceutical
The nutraceutical plant of Divi’s Laboratories is an integrated facility for the production of API and finished forms of Carotenoids. The company supplies carotenoids to major food, dietary supplement and feed manufacturers around the world.
Divis Laboratories Financial Highlights
- Revenue: Divis Laboratories reported revenue of ₹11,067.00 crore in FY26 vs ₹9,712.00 crore in FY25. It showed an increase of 13.95% on a yearly basis.
- Operating Profit: Divis Laboratories reported an operating profit of ₹3,388.00 crore in FY26 vs ₹2,916.00 crore in FY25. It showed an increase of 16.19% on a year-on-year basis.
- Net Profit: Divis Laboratories reported a net profit of ₹2,568.00 crore in FY26 vs ₹2,191.00 crore in FY25. It showed an increase of 17.21% on a yearly basis.
Divis Laboratories Quarterly Result Highlights
- Divis Laboratories reported revenue of ₹3,144.00 crore in Jun 2026, compared with ₹2,986.00 crore in Mar 2026, representing an increase of 5.29% on a quarter-on-quarter (QoQ) basis.
- Divis Laboratories reported an operating profit of ₹1,180.00 crore in Jun 2026, compared with ₹963.00 crore in Mar 2026, representing an increase of 22.53% on a quarter-on-quarter (QoQ) basis.
- Divis Laboratories reported a profit of ₹902.00 crore in Jun 2026, compared with ₹751.00 crore in Mar 2026, reflecting an increase of 20.11% on a QoQ basis.
- The earnings per share (EPS) of Divis Laboratories stood at ₹96.75 during Jun 2026.
Data Source: BSE, Company announcements
Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.
